HALO   $59.51  -4.49% Market Closed After Close 59.59 0.13%

Halozyme Therapeutics Inc
Total Cash 529.03M
totalCashPerShare 4.176
EBITDA 480.80M
Total Debt 1.53B
quickRatio 5.576
currentRatio 7.407
Total Revenue 873.30M
debtToEquity 529.735
Revenue/Share 6.783
ROA 0.1338
ROE 1.5315601
grossProfits
freeCashflow 335.21M
operatingCashflow 419.99M
earningsGrowth 0.29
revenueGrowth 0.047
grossMargins 0.70931
ebitdaMargins 0.55055
operatingMargins 0.50674
profitMargins 0.38623002
enterpriseValue 8.90B
forwardPE 13.006263
floatShares 125.34M
sharesOutstanding 126.68M
sharesShort 10.04M
sharesShortPriorMonth 8.95M
dateShortInterest
sharesPercentSharesOut 0.08%
heldPercentInsiders 0.01%
heldPercentInstitutions 0.98%
Short Ratio help_outline 7.57%
shortPercentOfFloat 0.11%
impliedSharesOutstanding
bookValue 2.287
Price To Book help_outline 27.24
earningsQuarterlyGrowth 0.25
netIncomeToCommon 337.29M
trailingEps 2.58%
forwardEps 4.79%
enterpriseToEbitda 18.50
lastDividendValue
lastDividendDate
currentQuarterEstimate 1.0 3Q 2024
institutionsCount 628
lastUpdated Sept. 16, 2024, 12:29 p.m.